Hem › Kronisk lymfatisk leukemi › Michigan
Kliniska studier för Kronisk lymfatisk leukemi i Michigan
12 studier för Kronisk lymfatisk leukemi söker deltagare vid platser i Michigan.
Städer i Michigan
- Detroit7 studier
- Grand Rapids5 studier
- Lansing3 studier
- Livonia3 studier
- Ann Arbor3 studier
- Canton3 studier
- Waterford3 studier
- Kalamazoo3 studier
Officiell studietext (engelska)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- och 4 fler
RekryterarFas 3
Ålder 65 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- och 68 fler
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- och 43 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- The Cancer and Hematology Centers, Grand Rapids
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Karmanos Cancer Institute, Detroit
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Corewell Health the Michigan Cancer Consortium, Grand Rapids
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Karmanos Cancer Institute, Detroit
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 28 sep. 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Karmanos Cancer Center, Detroit
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 17 sep. 2026 · NCT07221500Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- West Michigan Cancer Center, Kalamazoo
RekryterarObservationsstudie
Ålder 18 och äldre · Alla kön · Uppdaterad 7 maj 2026 · NCT02269592A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Henry Ford Hospital /ID# 270973, Detroit
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 9 apr. 2026 · NCT06428019HPC Offered for PRESERVE Expansion
- Henry Ford Health, Detroit
RekryterarObservationsstudie
Ålder 12 till 80 · Alla kön · Uppdaterad 28 aug. 2025 · NCT07145411Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.